OncoMatch/Clinical Trials/NCT07261631
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Is NCT07261631 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including 68Ga-NNS309 and 177Lu-DFC413 for pancreatic ductal adenocarcinoma.
Treatment: 68Ga-NNS309 · 177Lu-DFC413 — The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-DFC413 and safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with solid tumors
Check if I qualifyExtracted eligibility criteria
Treatments studied
Radioligand therapy
Other
Cancer type
Pancreatic Cancer
Non-Small Cell Lung Carcinoma
Triple-Negative Breast Cancer
Breast Carcinoma
Colorectal Cancer
Sarcoma
Demographics
Prior therapy
Must have received: cytotoxic chemotherapy — PDAC, NSCLC (no actionable alteration), CRC
disease progression following, or intolerance to cytotoxic therapy/chemotherapy
Must have received: chemotherapy and immunotherapy — NSCLC (no actionable alteration)
disease progression following, or intolerance to chemotherapy and immunotherapy
Must have received: chemotherapy and targeted therapy — NSCLC with actionable alteration
disease progression following, or intolerance to chemotherapy and targeted therapy
Must have received: hormone therapy and CDK4/6 inhibitor and at least one additional line — HR+/HER2- breast cancer
disease progression following, or intolerance to, hormone therapy and CDK inhibitor, and at least one additional line of therapy
Must have received: at least two lines of therapy — TNBC
disease progression following, or intolerance to, at least two lines of therapy
Must have received: at least one line of systemic therapy — soft tissue sarcoma
disease progression following, or intolerance to, at least one line of systemic therapy
Must have received: immune checkpoint inhibitor — CRC with MSI-H or dMMR
disease progression following, or intolerance to, immune checkpoint inhibitor therapy
Cannot have received: radioligand therapy
Any prior radioligand therapy
Cannot have received: radiation therapy
Exception: within 4 weeks prior to the first dose
Radiation therapy within 4 weeks prior to the first dose of [177Lu]Lu-DFC413
Lab requirements
Blood counts
anc ≥ 1.5 x 10^9/l, hemoglobin ≥ 9 g/dl, platelet count ≥ 100 x 10^9/l
Kidney function
egfr ≥ 60 ml/min, calculated using ckd-epi 2021 or measured
Cardiac function
qtcf < 470 msec
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07261631 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radioligand therapy, radiation therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 100 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify